These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17397121)

  • 1. A small molecule targeting the multifactorial nature of Alzheimer's disease.
    Cavalli A; Bolognesi ML; Capsoni S; Andrisano V; Bartolini M; Margotti E; Cattaneo A; Recanatini M; Melchiorre C
    Angew Chem Int Ed Engl; 2007; 46(20):3689-92. PubMed ID: 17397121
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure-activity relationships of memoquin: Influence of the chain chirality in the multi-target mechanism of action.
    Bolognesi ML; Bartolini M; Rosini M; Andrisano V; Melchiorre C
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4312-5. PubMed ID: 19505825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the photostability properties of memoquin, a quinone derivative for the treatment of Alzheimer's disease.
    Mancini F; Bolognesi ML; Melchiorre C; Andrisano V
    J Pharm Biomed Anal; 2009 Sep; 50(2):164-70. PubMed ID: 19464839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BACE-1 inhibitors part 3: identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells.
    Beswick P; Charrier N; Clarke B; Demont E; Dingwall C; Dunsdon R; Faller A; Gleave R; Hawkins J; Hussain I; Johnson CN; MacPherson D; Maile G; Matico R; Milner P; Mosley J; Naylor A; O'Brien A; Redshaw S; Riddell D; Rowland P; Skidmore J; Soleil V; Smith KJ; Stanway S; Stemp G; Stuart A; Sweitzer S; Theobald P; Vesey D; Walter DS; Ward J; Wayne G
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1022-6. PubMed ID: 18171615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs).
    Clarke B; Demont E; Dingwall C; Dunsdon R; Faller A; Hawkins J; Hussain I; MacPherson D; Maile G; Matico R; Milner P; Mosley J; Naylor A; O'Brien A; Redshaw S; Riddell D; Rowland P; Soleil V; Smith KJ; Stanway S; Stemp G; Sweitzer S; Theobald P; Vesey D; Walter DS; Ward J; Wayne G
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1011-6. PubMed ID: 18171614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BACE-1 inhibitors part 2: identification of hydroxy ethylamines (HEAs) with reduced peptidic character.
    Clarke B; Demont E; Dingwall C; Dunsdon R; Faller A; Hawkins J; Hussain I; MacPherson D; Maile G; Matico R; Milner P; Mosley J; Naylor A; O'Brien A; Redshaw S; Riddell D; Rowland P; Soleil V; Smith KJ; Stanway S; Stemp G; Sweitzer S; Theobald P; Vesey D; Walter DS; Ward J; Wayne G
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1017-21. PubMed ID: 18166458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.
    Mayer SC; Kreft AF; Harrison B; Abou-Gharbia M; Antane M; Aschmies S; Atchison K; Chlenov M; Cole DC; Comery T; Diamantidis G; Ellingboe J; Fan K; Galante R; Gonzales C; Ho DM; Hoke ME; Hu Y; Huryn D; Jain U; Jin M; Kremer K; Kubrak D; Lin M; Lu P; Magolda R; Martone R; Moore W; Oganesian A; Pangalos MN; Porte A; Reinhart P; Resnick L; Riddell DR; Sonnenberg-Reines J; Stock JR; Sun SC; Wagner E; Wang T; Woller K; Xu Z; Zaleska MM; Zeldis J; Zhang M; Zhou H; Jacobsen JS
    J Med Chem; 2008 Dec; 51(23):7348-51. PubMed ID: 19012391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent.
    Charrier N; Clarke B; Demont E; Dingwall C; Dunsdon R; Hawkins J; Hubbard J; Hussain I; Maile G; Matico R; Mosley J; Naylor A; O'Brien A; Redshaw S; Rowland P; Soleil V; Smith KJ; Sweitzer S; Theobald P; Vesey D; Walter DS; Wayne G
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3669-73. PubMed ID: 19477642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity.
    Bolognesi ML; Bartolini M; Tarozzi A; Morroni F; Lizzi F; Milelli A; Minarini A; Rosini M; Hrelia P; Andrisano V; Melchiorre C
    Bioorg Med Chem Lett; 2011 May; 21(9):2655-8. PubMed ID: 21236667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease.
    Bolognesi ML; Cavalli A; Melchiorre C
    Neurotherapeutics; 2009 Jan; 6(1):152-62. PubMed ID: 19110206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of novel N-aryl sulfonamide substituted 3-morpholino arecoline derivatives as muscarinic receptor 1 agonists in Alzheimer's dementia models.
    Kumar YC; Malviya M; Chandra JN; Sadashiva CT; Kumar CS; Prasad SB; Prasanna DS; Subhash MN; Rangappa KS
    Bioorg Med Chem; 2008 May; 16(9):5157-63. PubMed ID: 18359231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.
    Charrier N; Clarke B; Cutler L; Demont E; Dingwall C; Dunsdon R; Hawkins J; Howes C; Hubbard J; Hussain I; Maile G; Matico R; Mosley J; Naylor A; O'Brien A; Redshaw S; Rowland P; Soleil V; Smith KJ; Sweitzer S; Theobald P; Vesey D; Walter DS; Wayne G
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3664-8. PubMed ID: 19428244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatments and therapeutic targets in Alzheimer's disease.
    Zlokovic BV
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1533-7. PubMed ID: 12453670
    [No Abstract]   [Full Text] [Related]  

  • 14. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.
    Boissonneault V; Filali M; Lessard M; Relton J; Wong G; Rivest S
    Brain; 2009 Apr; 132(Pt 4):1078-92. PubMed ID: 19151372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
    Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
    Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystatin C: a potential target for Alzheimer's treatment.
    Levy E
    Expert Rev Neurother; 2008 May; 8(5):687-9. PubMed ID: 18457524
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic strategies and Alzheimer's disease: contribution of animal models].
    Chabrier PE
    Ann Pharm Fr; 2009 Mar; 67(2):97-103. PubMed ID: 19298893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." Alzheimer's disease drugs: more than one barrier to breach.
    Roher AE; Kokjohn TA
    Alzheimers Dement; 2009 Sep; 5(5):437-8. PubMed ID: 19751925
    [No Abstract]   [Full Text] [Related]  

  • 19. Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks.
    Bolognesi ML; Cavalli A; Bergamini C; Fato R; Lenaz G; Rosini M; Bartolini M; Andrisano V; Melchiorre C
    J Med Chem; 2009 Dec; 52(23):7883-6. PubMed ID: 19813747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of cyclo-phen-type ligands: chelators of metal ions as potential therapeutic agents in the treatment of neurodegenerative diseases.
    Boldron C; Van der Auwera I; Deraeve C; Gornitzka H; Wera S; Pitié M; Van Leuven F; Meunier B
    Chembiochem; 2005 Nov; 6(11):1976-80. PubMed ID: 16208731
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.